UNSPSC 51333510: Domperidone maleate

This classification denotes an antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 899U5WF46A. European Medicines Agency schedules Domperidone maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01815MIG. Domperidone maleate generally arises in the molecular formula C22H24CLN5O2.C4H4O4. The term 'domperidone maleate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule domperidone maleate under HS 29333999 and SITC 51574.

As of Q4 2014, DOMPERIDONE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC2C(C1)[NH]C(=O)N2CCCN3CCC(CC3)N4C5CCC(CC5[NH]C4=O)CL.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51333510 Domperidone maleate is a Commodity code that presents a significant mismatch between its nominal pharmaceutical scope and recent state and local procurement activity. The single recent opportunity tagged to this code — Seminole County, Florida's IFB 60459723LAS posted June 30, 2026 — solicits Naloxone and Safe Drug Deactivation Systems, products unrelated to domperidone maleate. The county procurement does not reflect the antiemetic pharmaceutical agent the code nominally describes, and no recent state and local opportunities in the source actually solicit domperidone maleate itself.

The Seminole County IFB, with a response deadline of July 26, 2023, is the only recent opportunity present in the source and does not support reliable characterization of issuing-body patterns, geographic concentration, or representative procurement activity under this code. State and local governments may procure domperidone maleate through other channels or under different code classifications, but the source provides no evidence of current activity aligned with the code's stated scope. Firms evaluating this code should verify whether state and local buyers are categorizing domperidone procurement under alternative UNSPSC classifications or whether procurement volume in this category has shifted to different pharmaceutical products or vendors.